These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27480588)

  • 1. Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy".
    Carrat F; Nahon P; Duclos-Vallée JC; Pageaux GP; Fontaine H; Pol S;
    J Hepatol; 2016 Dec; 65(6):1269-1270. PubMed ID: 27480588
    [No Abstract]   [Full Text] [Related]  

  • 2. A strong message is needed to address the issue of HCC recurrence after DAA therapy.
    Kolly P; Dufour JF
    J Hepatol; 2016 Dec; 65(6):1268-1269. PubMed ID: 27480589
    [No Abstract]   [Full Text] [Related]  

  • 3. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
    ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
    J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
    Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S
    J Hepatol; 2016 Oct; 65(4):727-733. PubMed ID: 27349488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".
    Reig M; Torres F; Mariño Z; Forns X; Bruix J
    J Hepatol; 2016 Oct; 65(4):864-865. PubMed ID: 27255581
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.
    Tsai PC; Huang CF; Yu ML
    J Hepatol; 2017 Feb; 66(2):464. PubMed ID: 27840227
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?
    Alberti A; Piovesan S
    Liver Int; 2017 Jun; 37(6):802-808. PubMed ID: 28544696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.
    Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixco C; Decaestecker J; de Galocsy C; Janssens F; Van Overbeke L; Van Steenkiste C; D'Heygere F; Cool M; Wuyckens K; Nevens F; Robaeys G
    J Viral Hepat; 2017 Nov; 24(11):976-981. PubMed ID: 28504854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
    Cabibbo G; Petta S; Calvaruso V; Cacciola I; Cannavò MR; Madonia S; Distefano M; Larocca L; Prestileo T; Tinè F; Bertino G; Giannitrapani L; Benanti F; Licata A; Scalisi I; Mazzola G; Cartabellotta F; Alessi N; Barbàra M; Russello M; Scifo G; Squadrito G; Raimondo G; Craxì A; Di Marco V; Cammà C;
    Aliment Pharmacol Ther; 2017 Oct; 46(7):688-695. PubMed ID: 28791711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
    Huang G; Lau WY; Wang ZG; Pan ZY; Yuan SX; Shen F; Zhou WP; Wu MC
    Ann Surg; 2015 Jan; 261(1):56-66. PubMed ID: 25072444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y
    World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.
    Cammà C; Cabibbo G; Craxì A
    J Hepatol; 2016 Oct; 65(4):861-862. PubMed ID: 27255578
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
    Nakao Y; Hashimoto S; Abiru S; Komori A; Yamasaki K; Nagaoka S; Saeki A; Bekki S; Kugiyama Y; Kuroki T; Ito M; Nakao K; Yatsuhashi H
    J Hepatol; 2018 Apr; 68(4):854-855. PubMed ID: 29146486
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.